How this company measures up on the fundamentals that matter
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $162, 48% above fair value of $109. Passes all ethical screens. Ranks better than 54% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | ZERHOUNI ELIAS A | Director | 680 | — | |
| 2026-05-15 | SPOON ALAN G | Director | 680 | — | |
| 2026-05-15 | LIST-STOLL TERI L. | Director | 680 | — | |
| 2026-05-15 | STEVENS RAYMOND C | Director | 680 | — | |
| 2026-05-15 | LAMANNA CHARLES W | Director | 680 | — | |
| 2026-05-15 | DEWAN FEROZ | Director | 680 | — | |
| 2026-05-15 | SANDERS A.SHANE | Director | 680 | — | |
| 2026-05-15 | FILLER LINDA | Director | 680 | — | |
| 2026-05-01 | SPOON ALAN G | Director | 1,358 | $237,207 | |
| 2026-05-01 | SPOON ALAN G | Director | 3,298 | $237,060 |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15